Cancer care is undergoing a major transformation with the rise of targeted radionuclide therapy, particularly Lutetium-177 (Lu-177)–based treatments. These therapies represent a shift from conventional, non-specific approaches to precision oncology, where cancer cells are selectively targeted while preserving healthy tissue.
Cancer imaging is rapidly evolving, and FAPI imaging is emerging as one of the most promising advances in modern nuclear medicine. Unlike tracers such as FDG—which reflect glucose metabolism in tumor cells—FAPI targets fibroblast activation protein (FAP), a key marker expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment.
Prostate cancer care has entered a new era with the introduction of PSMA PET imaging—a highly sensitive technique that can detect prostate cancer throughout the body with remarkable accuracy.